Take the blood test, and give the drug, at the right time of day
Cancer cells enter the blood mostly during rest, so a morning blood test may miss them. Sampling and dosing at the right hour may be a free improvement.
Circulating tumour cell shedding in breast cancer patients and mouse models peaks during the rest phase, with several-fold differences between night and day samples. Almost all clinical sampling occurs in clinic hours, and almost all therapy is delivered in clinic hours. If shedding and proliferation are circadian, both assay sensitivity and drug timing are currently set by convenience.
- Dormant cells and minimal residual disease · After a 'successful' treatment, cells can sleep for years then relapse. We can barely detect them and cannot target them.
- Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.
Pages like this
not linked directly; found by shared links- IdeaCirculating tumour cell clearance as the phase 2 gate for anti-metastatic drugs
Shares Klaus Pantel, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), Biomarkers are not validated or standardised.
- IdeaRead the spinal fluid to track brain tumours without opening the skull
Shares Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Biomarkers are not validated or standardised.
- PersonSarah-Jane Dawson
Shares Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), HR-positive / HER2-negative breast cancer.
- PersonAsh A. Alizadeh
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaBank yearly blood from cancer survivors so future tests can be validated
Shares Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaHPV circulating tumour DNA to guide cervical cancer therapy
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaCertified reference samples to benchmark every tumour-DNA blood test
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), Biomarkers are not validated or standardised, MRD / molecular residual disease testing.
- IdeaBlunt the inflammation that wakes sleeping cancer cells
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, HR-positive / HER2-negative breast cancer.